Skip to main content

Author: Louise Stanley

DaRe2THINK launches enhanced digital platform to transform clinical trials for GP practices

Written by Louise Stanley on . Posted in Clinical trials, Health inequalities.

A new digital platform has been launched to transform how NHS GP practices take part in clinical trials, making research quicker, easier and more inclusive for patients across the UK.

The DaRe2THINK clinical trial, led by BHP founder-member the University of Birmingham and the Clinical Practice Research Datalink (CPRD; part of the Medicines and Healthcare products Regulatory Agency), and run in partnership with NHS providers and the NIHR Research Delivery Network, has developed the platform to reduce paperwork for GP staff and reach communities often underrepresented in research.

The platform securely links to existing GP systems, automatically transferring relevant health data to participating NHS General Practices, significantly reducing administrative burden on clinical staff. The enhanced functionality enables practice staff to rapidly identify suitable patient cohorts for NHS clinical trials and engage participants through integrated mobile messaging systems.

DaRe2THINK already securely screens routine healthcare records from over 13 million NHS patients across more than 450 General Practices in England. This builds upon efforts to embed research into everyday NHS care.

Puja Myles, Director of CPRD at the MHRA, said: “This platform represents a paradigm shift in how we conduct primary care research. By leveraging routine health data and advanced digital tools, we’re removing traditional barriers that have prevented many communities from accessing the benefits of clinical trial participation.”

The current DaRe2THINK trial is investigating whether earlier intervention with NHS treatments can prevent blood clots and memory loss in patients with atrial fibrillation, a common heart rhythm condition associated with vascular dementia. Notably, 25% of participating practices are in England’s most health-deprived areas, addressing long-standing inequalities in clinical research participation.

Dipak Kotecha, Professor of Cardiology at the University of Birmingham, said: “DaRe2THINK is leading the way to empower patients and provide an opportunity to take part in NHS clinical trials.

“The enhanced digital platform has now been rolled out across England, making it quicker and simpler for NHS staff to reach out to their patients, and embedding prevention into routine care.”

Dr Alexandra Lee, a General Practitioner at University of Birmingham, said: “The digital trial platform used in DaRe2THINK has had a positive impact on the delivery of primary care research and has helped recruit a new cohort of general practices that haven’t previously taken part in clinical trials.”

Charles Michaleis, a DaRe2THINK Participant, said: “The DaRe2THINK study was very easy to sign up to and get involved in, with the hope that this will lead to improved treatments for NHS patients who have atrial fibrillation.”

The trial is funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme and supported by a dedicated public engagement team. The research was carried out at the NIHR Birmingham Biomedical Research Centre (BRC), a cross-BHP collaboration hosted by University Hospitals Birmingham.

DaRe2THINK aims to democratise access to clinical trials across all communities; the platform’s development aligns with the NHS People Plan to foster inclusive research culture and supports the broader goal of improving efficiency in community-based clinical trials.

A year of growth, innovation and partnership

Written by Louise Stanley on . Posted in Birmingham Health Partners.

Following a year in which Birmingham Health Partners organisations won more than £70m of research investments from NIHR and other funders, signed a strategic partnership with ABHI, and launched its BHP People reward and recognition scheme – we’re pleased to publish our fourth annual review of activity for the period September 2024-August 2025. 

In their foreword, Professors Lorraine Harper (Managing Director) and Neil Hanley (Executive Director), said:

“The past 12 months have been exceptionally busy across Birmingham Health Partners. Our flagship Reducing Bureaucracy in Clinical Trials theme has gone from strength to strength and is complemented by the fantastic news we received in December – the success of our bid to lead one of the new NIHR Commercial Research Delivery Centres (CRDCs), which aim to expand access to clinical trials to some of the country’s most underserved communities.

“In June, we welcomed colleagues from the Association of British HealthTech Industries (ABHI) to Birmingham, where we signed up to a landmark strategic partnership focused on improving clinical outcomes, addressing health inequalities, and ensuring that health technologies are scalable and relevant to population health. We look forward to continuing collaborations with ABHI and its members.

“June also saw the opening of the Precision Health Technologies Accelerator (PHTA), the University of Birmingham’s flagship research facility and anchor tenants at the new Birmingham Health Innovation Campus. This represents a golden opportunity for BHP researchers to commercialise innovations, provide consultancy to SMEs, and collaborate across the ecosystem.

“Significant progress has also been made with our Patient and Public Involvement and Engagement (PPIE) theme, which brings together the excellent work of our individual member organisations and provides a comprehensive suite of resources to help enhance our collective PPIE practice to ensure the patient voice is not only heard, but helps to shape and direct research.

“As ever, we are immensely proud of the achievements of all our member organisations, some of which are captured in our case study round-up which represent a mix of initiatives directly convened by BHP, and examples of exceptional innovation and collaboration from across the partnership.

“The efforts of every individual involved in research continue to benefit patients, whether it is through improving cancer outcomes, enhancing mental health research, tackling inflammation and chronic disease, or improving maternal and perinatal health across our community.

“Finally, we extend our sincere thanks to our outgoing chair, Jonathan Pearson, for his guidance over the past two years. His leadership has been clear, and always centred on what matters – people. We are delighted that Jonathan will remain a key figure in BHP through his new appointment as Chair of Health Innovation West Midlands, which will no doubt benefit from his expertise.”

View and download the BHP Annual Review of Activity 2024-2025.

Professor Andrew Filer appointed Director of NIHR Birmingham Biomedical Research Centre

Written by Louise Stanley on . Posted in Birmingham Health Partners, Inflammation and chronic disease.

The National Institute for Health and Care Research (NIHR) Birmingham Biomedical Research Centre (BRC) has announced the appointment of Professor Andrew Filer as its new Director. Professor Filer takes over from Professor Paul Moss, who has served as Interim Director since June 2024.

Professor Filer is already co-lead of the BRC’s Inflammatory Arthritis research theme and brings a wealth of clinical and translational research experience to the role. His leadership will further guide the BRC in delivering cutting-edge research that transforms patient care across the region and beyond.

Professor Filer said: “I’m honoured to take on the role of Director at such an exciting time for the Birmingham BRC. Our BRC is built on a foundation of collaboration, innovation and clinical excellence. I look forward to working with our partners to ensure our research continues to make a real difference to patients’ lives.”

The NIHR Birmingham BRC is a cross-BHP collaboration, hosted by University Hospitals Birmingham NHS Foundation Trust (UHB) and delivered in partnership with the University of Birmingham and six associate academic and NHS partners across the region. It brings together clinicians, scientists and healthcare professionals to drive translational research improving outcomes for people with inflammatory diseases.

Professor Kiran Patel, Chief Medical Officer at UHB, said: “Professor Filer is passionate about integrating patient-centred approaches and high-quality discovery science to drive innovation. I am delighted he has taken on this role, and I am sure he will provide effective leadership to our incredibly successful NIHR Birmingham BRC.”

Professor Neil Hanley, Pro-Vice-Chancellor and Head of the College of Medicine and Health at the University of Birmingham, added: “I’m really excited by Andrew’s appointment. It really does reflect the strength of clinical research leadership in Birmingham. His vision and energy will be instrumental for the next phase of the BRC’s mission to deliver inclusive impact, health improvement and economic growth.”

Dr Victoria Day, Head of Infrastructure at the Birmingham BRC, commented: “Andrew brings deep knowledge of the NIHR landscape and a long-standing commitment to patient-focused research. His leadership and collaborative approach will be key to driving the Birmingham BRC forward and delivering meaningful health impact.

“I would like to take this opportunity to sincerely thank Professor Paul Moss for his support during his time as Interim Director. His leadership and commitment have contributed to the many achievements we’ve made during this period.”

Professor Andrew Filer is a Professor of Translational Rheumatology in the Department of Inflammation and Ageing at the University of Birmingham. A Fellow of the Royal College of Physicians, he holds a PhD in immunology and is an Honorary Consultant Rheumatologist. He is internationally recognised for his work in early inflammatory arthritis, particularly in developing novel imaging and biopsy techniques to study disease mechanisms and improve diagnosis.

He co-leads the Birmingham Early Arthritis Clinic and has pioneered the use of musculoskeletal ultrasound and ultrasound-guided synovial biopsy in clinical research. His research focuses on Synovial cellular biology, disease stratification, and the development of targeted therapies for rheumatoid arthritis. Professor Filer is a passionate advocate for integrating patient cohorts with high-quality basic science to accelerate translational impact.

BHP’s health inequalities lead awarded prestigious NIHR Research Professorship

Written by Louise Stanley on . Posted in Birmingham Health Partners, Health inequalities.

Our health inequalities theme lead Professor Joht Singh Chandan – from the University of Birmingham’s Department of Applied Health Sciences – has been awarded one of six prestigious NIHR Research Professorships by the National Institute for Health and Care Research (NIHR).

As the NIHR’s flagship award for leading researchers, this Professorship is highly prestigious and supports individuals with an outstanding track record of applied health and care research to undertake high-impact work that will shape the future of healthcare in the UK and beyond.

Professor Chandan was recognised last year as the youngest clinical professor in the UK, bringing extensive expertise across the fields of violence against women and girls, maternal health, and public health, especially addressing health inequalities in underserved communities. Most recently, he has been announced as the co-lead of the NIHR’s new Challenge Maternity Disparities Consortium bringing together nine UK universities with the aim of tackling inequalities in maternity care. Professor Chandan retains a longstanding commitment to advancing research, policy and practice in these critical areas, with work that has shaped national conversations for vulnerable populations.

“I’m deeply honoured to receive this NIHR Research Professorship,” Professor Chandan said. “Violence against women and children is one of the greatest public health challenges of our time, and survivors deserve a healthcare system that truly listens, understands, and responds to their needs. This award will allow me to work alongside individuals, families, and communities affected by violence to co-produce a more trauma-informed and equitable NHS – helping to build safer, more supportive services for everyone affected by violence.”

The five-year Research Professorship award includes funding for research costs, a leadership development programme, and support for building a research team. It is designed to strengthen the UK’s capacity for world-leading applied health research and ensure that discoveries are rapidly translated into practice.

This new professorship will enable Professor Chandan to work closely with survivors of violence to close the gaps between them and avenues of support such as local authority settings and the NHS. This work is undertaken with a view to expanding this work nationally, building research capacity, and helping to create safer, more supportive, and informed healthcare services for survivors of violence.

Despite growing awareness, significant gaps remain in the support of survivors of violence within healthcare systems. Further research is urgently needed to develop evidence-based interventions, improve service accessibility, and ensure that care is both trauma-informed and culturally sensitive for those from underserved communities. Professor Chandan also co-leads the NIHR Global Health Research Group on Violence Against Women and Children, which brings together researchers and practitioners across eleven countries to share learning and develop scalable solutions, ensuring that insights from the UK inform, and are informed by, global efforts to tackle violence.

Professor Lucy Chappell, Chief Executive Officer of the NIHR and Chief Scientific Adviser at the Department of Health and Social Care, said: “I am delighted to welcome this new cohort of NIHR Research Professors. As well as recognising individual excellence, these awards are a strategic investment in our research leadership across health, social care and public health.

“I look forward to seeing the positive impact of these awardees’ research and leadership across major health and care challenges.”

NIHR Research Professorships are among the UK’s most prestigious career development awards. The awards are focussed on translating into real world impact. The 10 Year Health Plan recognised the need for research and innovation to be integrated into health and care practice.

NIHR Research Professors combine their academic roles with professional practice. They provide a crucial link between research and the delivery of health, social care and public health services, driving the implementation of evidence-based improvements that address key health and social care challenges.

Trial offers new hope to patients with rare skin cancer

Written by Louise Stanley on . Posted in Cancer outcomes, Clinical trials, Experimental medicine.

Researchers at BHP founder-members University Hospitals Birmingham have contributed to new findings showing that patients with Cutaneous (skin) T-cell Lymphoma (CTCL) experienced improved overall survival when treated with mogamulizumab, known by its brand name POTELIGEO.

CTCL is a rare type of cancer that begins in the white blood cells and affects the skin, causing rashes and slightly raised or scaly round patches. The most common types are mycosis fungoides and Sézary syndrome, with around 150 people diagnosed in the UK each year.

Individual’s experiences with CTCL can vary wildly – many people experience only a mild form that is not life-threatening and can be managed for years, while a smaller number develop a more serious form. Treatments either target the skin directly, using creams, light therapy, or radiotherapy, or are given as tablets or injections that circulate in the blood and work throughout the body.

POTELIGEO (mogamulizumab) is a prescription medicine given by injection into a vein and is used to treat mycosis fungoides or Sézary syndrome in adults whose disease has returned or who have not responded to at least one other treatment (oral or injectable).

Now in its tenth year, the PROCLIPI Study is the largest international study of its kind, involving 2,547 patients across 19 countries. It collects information on tests, scans, treatments, quality of life, and survival from CTCL patients, with the aim of developing a tool (known as a prognostic index) to predict outcomes for people with the disease.

The latest research confirmed that patients with advanced-stage disease treated with POTELIGEO experienced improved overall survival, with a median overall survival of 64 months compared to 54 months for patients who did not receive the treatment.

Professor Julia Scarisbrick, Consultant Dermatologist at UHB and Chief Investigator, said: “The PROCLIPI Study demonstrates the power of global collaboration in rare diseases. By bringing together data from across the world, we can generate insights that simply wouldn’t be possible in isolation.

“We are proud to coordinate this initiative here in Birmingham in partnership with Prof Kim at Stanford University, California, as we’re working to build rigorous scientific evidence while giving patients and their families a better understanding of what long-term survival looks like.”

Alexandra Mars, a 51-year-old patient at UHB’s Queen Elizabeth Hospital took part in the study, and said: “I have had tumour mycosis fungoides for over 10 years. I was most recently treated with mogamulizumab for two years and had no significant side effects. It appears to have put my disease to sleep, and I have not been on any medication since February. It is amazing to finally be able to have a break from treatment, which is so tiring, and not have to think about this disease.”

Due to the rarity of CTCL and its wide variation in presentation and progression, enrolling patients in clinical trials can be challenging. Despite these difficulties, growing evidence is helping doctors understand which treatments may be most beneficial.

Top rating for Birmingham’s NIHR Integrated Clinical Academic Training programme

Written by Louise Stanley on . Posted in Birmingham Health Partners.

The Integrated Clinical Academic Training (ICAT) programme led by BHP founder-member the University of Birmingham, has been rated joint top alongside the University of Oxford.

Birmingham’s ICAT programme is one of 36 across the country, with its NIHR funding complemented by posts supported by fellow Birmingham Health Partners member organisations. It provides opportunities for medical and dental graduates to have dedicated research time alongside their clinical training and NHS commitments and is critical to developing the future clinical research workforce, supporting clinicians to pursue research interests alongside clinical practice.

The University excelled in the recent NIHR funding competition, being awarded 28 Academic Clinical Fellow posts and 13 Academic Clinical Lecturer posts, for the period 2026 and 2027.

“We are proud to be one of the largest of the 36 NIHR ICAT programmes in the country, with 116 current trainees, ranging from pre-doctoral Academic Clinical Fellows to consultant level, postdoctoral Birmingham Health Partners award holders. Our relationships with NHS trusts across the region through BHP stand us apart from many of the other ICAT programmes and this partnership is integral to building regional research leadership capacity,” said Professor Kristien Boelaert, ICAT Academic Lead and Professor of Endocrinology at the University.

Earlier this year, the Medical Schools Council highlighted a trend in declining numbers of clinical academics and called for intervention to safeguard the future of medical research and education. The Government’s 10 Year Health plan recognises the importance of embedding research across healthcare to drive reform and attracting early career clinicians to academia is essential to increase those numbers.

Commenting on the importance of Birmingham’s contribution, Professor Boelaert explained: “It’s not just that we have an impressive number of posts here in Birmingham – our career development initiatives, research culture and peer support activities make up the full package. Our Research Retreat was also highlighted as very beneficial, along with outstanding feedback via our trainee experience survey.”

Since Birmingham’s ICAT Programme launched in 2015, 55 of our 86 NIHR Academic Clinical Fellows (64%) have progressed to clinical research training fellowships or other academic posts and 55 of 73 our NIHR and locally-funded Clinical Lecturers have progressed to senior academic positions (75%), including 17 as research-active consultants.

Find out more about our programmes:

  • BHP Starter Fellowships, allowing individuals to start their research career providing cost to cover one year’s salary to undertake a Master’s by Research
  • Clinical Academic Research Partnerships (CARP), to support individuals continue their research careers while delivering clinical service providing salary funding for two programmed activities (PAs) – or 8 hours per week – of protected research time for two years
  • New Consultant Scheme, providing salary funding for two programmed activities (PAs) – or 8 hours per week – of protected research time for three years
  • BHP Clinician Scientist, 50:50 appointments providing an academic consultant post linked with one of our NHS trusts to develop individuals as successful independent clinical researchers